Jump to content

Granules India: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
Rebootuni (talk | contribs)
20 edits
No edit summary
 
(47 intermediate revisions by 29 users not shown)
Line 1: Line 1:
{{Short description|Indian pharmaceutical company}}
{{COI|date=March 2015}}
{{COI|date=March 2015}}
{{primary sources|date=January 2015}}
{{Use dmy dates|date=May 2018}}
{{Use Indian English|date=May 2018}}

{{Infobox company
{{Infobox company
| name = Granules India Ltd.
| name = Granules India Ltd.
| logo = Granules India logo.svg
| logo = Granules India logo.svg
| image = Granules BPL plant.JPG
| image_caption = Granules plant in [[Bonthapally]]
| type = [[Public company|Public]]
| type = [[Public company|Public]]
| traded_as={{BSE|532482}}<br />{{NSE|GRANULES}}
| traded_as = {{BSE|532482}}<br />{{NSE|GRANULES}}
⚫
| industry = [[Pharmaceutical company|Pharmaceuticals]]
| foundation = 1984
| foundation = 1984
| founder = Mr. C. Krishna Prasad
| founder = Krishna Prasad Chigurupati
| location = [[Hyderabad (India)|Hyderabad]], [[India]]
| location = [[Hyderabad]], [[Telangana]], India
| area_served = Worldwide
| area_served = Worldwide
| key_people = C. Krishna Prasad ([[Chairman|CMD]])<br />Harsha Chigurupati ([[Executive director|ED]])<br />VVS Murthy ([[CFO]])<br />Madhusudhan Rao ([[Chief operating officer|COO]])<br />Stefan Lohle ([[Chief marketing officer|CMO]])
| key_people = Krishna Prasad Chigurupati ([[Chairman|CMD]])<br />Sandeep Neogi ([[CFO]])<br /> GSR Prasad ([[Chief operating officer|COO]])
⚫
| products = [[Paracetamol]], [[Ibuprofen]], [[Methocarbamol]], [[Metformin]], [[Guaifenesin]]
⚫
| industry = [[Pharmaceutical company|Pharmaceuticals]]
| revenue = {{down}} {{INRconvert|4506|c}} (FY24)<ref name="fy24"/>
| business segments = [[Finished Dosages]] ([[FDs]])<br />[[Pharmaceutical Formulation Intermediates]] ([[PFIs]])<br />[[Active Pharmaceutical Ingredients]] ([[APIs]])
| operating_income = {{down}} {{INRconvert|856|c}} (FY24)<ref name="fy24"/>
⚫
| products = [[Paracetamol]], [[Ibuprofen]], [[Methocarbamol]], [[Metformin]], [[Guaifenesin]], etc.
| profit = {{down}} {{INRconvert|405|c}} (FY24)<ref name="fy24">{{cite web |title=Earnings Presentation - Q4 & Full Year FY24 |url=https://www.bseindia.com/xml-data/corpfiling/AttachHis/2b4f9d1d-b4e2-4bfd-8f6d-32d5923e670f.pdf |website=BSE |publisher=Granules India Limited |access-date=10 July 2024}}</ref>
| revenue = FY 2013-14<br />[[Indian rupee|INR]] 1,096 [[Crore]]
⚫
| num_employees = 2,789
| net_profit = FY 2013-14 <br /> [[Indian rupee|INR]] 75 [[Crore]]
⚫
| homepage = {{URL|https://granulesindia.com}}
⚫
| num_employees= 1653
⚫
| homepage = [http://www.granulesindia.com/ www.granulesindia.com]
}}
}}


'''Granules India Limited''' is an Indian [[pharmaceutical]] manufacturing company based in [[Hyderabad (India)|Hyderabad]], India. The Company manufactures [[Tablet (pharmacy)|tablets]], [[Pharmaceutical Formulation Intermediates]] (PFIs) and [[active pharmaceutical ingredients]] (APIs) which are distributed in over 50 countries.<ref>{{cite web|url=http://www.granulesindia.com/Overview.aspx |title=Granules India Limited - About Us - Overview |publisher=Granulesindia.com |date= |accessdate=2010-09-30}}</ref> Granules manufactures several off-patent drugs, including Paracetamol, Ibuprofen, Metformin and Guaifenesin, on a large scale for customers in the regulated and semi-regulated markets.<ref>{{cite news|url=http://www.moneycontrol.com/news/business/granules-india-signs-dealmatchland-pty-ltd_270194.html|title=Granules India signs deal with Matchland Pty Ltd}}</ref><ref>{{cite news|url=http://www.thehindubusinessline.com/2007/05/10/stories/2007051001371700.htm|title=Granules India| date=May 10, 2007|work=Moneycontrol.com|accessdate=10 December 2009}}</ref>
'''Granules India Limited''' is an Indian multinational [[pharmaceutical]] manufacturing company based in [[Hyderabad]]. Granules manufactures several off-patent drugs, including [[Paracetamol]], [[Ibuprofen]], [[Metformin]] and [[Guaifenesin]], on a large scale for customers in the regulated and rest of the world markets. Granules India Limited also operates in the [[Contract research organization|contract research and manufacturing]] (CRAM) segment.<ref>{{cite news|url=http://www.moneycontrol.com/news/business/granules-india-signs-dealmatchland-pty-ltd_270194.html|title=Granules India signs deal with Matchland Pty Ltd}}</ref><ref>{{cite news|url=http://www.thehindubusinessline.com/2007/05/10/stories/2007051001371700.htm|title=Granules India| date=10 May 2007|work=Moneycontrol.com|accessdate=10 December 2009}}</ref>


==History==
==History==
Granules India was formed in 1984 as Triton Laboratories. Triton produced Paracetamol API at its Bonthapally factory on the outskirts of Hyderabad.<ref>{{cite web|url=https://www.zaubacorp.com/company/TRITON-LABORATORIES-NTD/U24231TG1984PLC004914}}</ref>
Granules India was formed in 1984 as Triton Laboratories. Triton produced Paracetamol API at its [[Bonthapally]] factory on the outskirts of Hyderabad.<ref>{{cite web|url=https://www.zaubacorp.com/company/TRITON-LABORATORIES-NTD/U24231TG1984PLC004914 | title=Triton Laboratories Ltd Company info}}</ref> Triton scientists found a more efficient way to produce the Paracetamol API, which led to lower capital and raw material requirements.{{citation needed|date=March 2015}} In 1987, Triton became the only Indian company aside from [[Dr. Reddy's Laboratories]] to export pharmaceutical products to the U.S.{{citation needed|reason=not in cited reference|date=March 2015}}<!-- <ref>{{cite news|url=http://www.moneycontrol.com/news/business/ifc-financing-to-support-growthgranules-india_287176.html|title=IFC financing to support growth of Granules India |date=June 18, 2007|work=Moneycontrol.com|accessdate=10 December 2009}}</ref> -->
Triton scientists found a more efficient way to produce the Paracetamol API, which led to lower capital and raw material requirements.{{cn|date=March 2015}} In 1987, Triton became the only Indian company aside from Dr. Reddy’s Laboratories to export pharmaceutical products to the U.S.{{cn|reason=not in cited reference|date=March 2015}}<!-- <ref>{{cite news|url=http://www.moneycontrol.com/news/business/ifc-financing-to-support-growthgranules-india_287176.html|title=IFC financing to support growth of Granules India |date=June 18, 2007|work=Moneycontrol.com|accessdate=10 December 2009}}</ref> -->


Though Triton was growing as an API manufacturer, management decided it could create a value added version of its product.{{cn|date=March 2015}} In order to distinguish itself from competitors, Triton management pioneered the concept of manufacturing and selling in bulk granulated Paracetamol, also known as direct compressible grade material (DC), or "PFI".{{cn|date=March 2015}} In 1990, it opened its second manufacturing facility at Jeedimetla to produce multiple APIs.
Though Triton was growing as an API manufacturer, management decided it could create a value added version of its product.{{citation needed|date=March 2015}} In order to distinguish itself from competitors, Triton management pioneered the concept of manufacturing and selling in bulk granulated Paracetamol, also known as direct compressible grade material (DC), or "PFI".{{citation needed|date=March 2015}} In 1990, it opened its second manufacturing facility at [[Jeedimetla]] to produce multiple APIs.


In 1991,<ref name="Granulesindia.com">{{cite web|url=http://www.granulesindia.com/Milestones.aspx |title=Granules India Limited - About Us - Milestones |publisher=Granulesindia.com |date= |accessdate=2010-09-30}}</ref> management set up a new entity, which was incorporated as Granules India Limited. Soon after Granules applied the PFI concept to other APIs, set up a PFI facility at Jeedimetla and began exporting the material to various markets including the U.S., Germany and Australia.<ref>{{cite news|url=http://www.moneycontrol.com/news/business/granules-ties-upgsk-healthcare-rd_262764.html|title=Granules ties up with GSK Healthcare R&D}}</ref>
In 1991,<ref name="Granulesindia.com">{{cite web |url=http://www.granulesindia.com/Milestones.aspx |title=Granules India Limited – About Us – Milestones |publisher=Granulesindia.com |date= |accessdate=2010-09-30 |archive-url=https://web.archive.org/web/20100717135916/http://www.granulesindia.com/Milestones.aspx |archive-date=17 July 2010 |url-status=dead }}</ref> management set up a new entity, which was incorporated as Granules India Limited. Soon after Granules applied the PFI concept to other APIs, set up a PFI facility at Jeedimetla and began exporting the material to various markets including the U.S., Germany and Australia.<ref>{{cite news|url=http://www.moneycontrol.com/news/business/granules-ties-upgsk-healthcare-rd_262764.html|title=Granules ties up with GSK Healthcare R&D}}</ref>


In 1995,<ref name="Granulesindia.com"/> Granules became a public company, after having [[initial public offering]]s on the Bombay and Hyderabad Stock Exchanges.<ref>{{cite news|url=http://www.business-standard.com/india/storypage.php?autono=257912|title=Granules, Amneal Pharma get FDA nod|date=August 2, 2006|work=Business Standard|accessdate=10 December 2009}}</ref>
In 1995,<ref name="Granulesindia.com"/> Granules became a public company, after having [[initial public offering]]s on the Bombay and Hyderabad Stock Exchanges.<ref>{{cite news|url=http://www.business-standard.com/india/storypage.php?autono=257912|title=Granules, Amneal Pharma get FDA nod|date=2 August 2006|work=Business Standard|accessdate=10 December 2009}}</ref>


In 2013, Granules India acquired Auctus Pharma for Rs 120 crore.<ref>{{Cite web|url=https://www.businesstoday.in/current/deals/granules-india-acquires-auctus-pharma/story/200299.html|title=Granules India acquires Auctus Pharma for Rs 120 crore|website=www.businesstoday.in|date=5 November 2013 |access-date=2020-02-10}}</ref>
In 2001, the API and PFI blocks at Jeedimetla facility received approval from the U.S. FDA.


In 2016, Granules India commissioned a new state of the art manufacturing unit that hosts facilities for Oncology and High Potent APIs. This new plant is located in [[Visakhapatnam district|Visakhapatnam]].
⚫
In 2002,<ref name="Granulesindia.com"/> Granules started building a new PFI plant in Gagillapur. The facility opened in August 2003. The facility is one of the largest of its kind in the world.{{cn|date=March 2015}} In order to secure API for its Ibuprofen PFI, Granules formed a joint-venture with Hubei Biocause Heilen Pharmaceutical to create Granules Biocause in Wuhan, China.<ref>{{cite web|url=http://www.in-pharmatechnologist.com/Materials-Formulation/Granules-India-takes-stake-in-Chinese-firm |title=Granules India takes stake in Chinese firm |publisher=In-pharmatechnologist.com |date= |accessdate=2010-09-30}}</ref> The jointly owned Ibuprofen plant is among the biggest plants of its kind in the world.<ref>{{cite news|url=http://www.granulesindia.com/News/News7.aspx|title= Granules India invites shareholders approval for IFC investment}}</ref>


⚫
In order to secure API for its Ibuprofen PFI, Granules formed a joint-venture with Hubei Biocause Heilen Pharmaceutical to create Granules Biocause in [[Wuhan]], China.<ref>{{cite web|url=http://www.in-pharmatechnologist.com/Materials-Formulation/Granules-India-takes-stake-in-Chinese-firm |title=Granules India takes stake in Chinese firm |publisher=In-pharmatechnologist.com |date= |accessdate=2010-09-30}}</ref> In 2019, Granules India Limited announced its intention to divest its entire equity shareholding in Granules Biocause Pharmaceuticals Co. Ltd. by selling its stake to joint venture partner.<ref>{{cite news |title=Granules India to divest its stake in its joint venture located in China |url=https://health.economictimes.indiatimes.com/news/pharma/granules-india-to-divest-its-stake-in-its-joint-venture-located-in-china/71596498 |work=Economic Times |language=en}}</ref>
In 2004, Granules obtained approval from U.S. FDA, Australian TGA and German Health Authority for the Gagillapur facility. In 2007, the Bonthapally new API facility was audited and approved by the FDA.<ref name="http">{{cite web|url=http://www.granulesindia.com/News/News8.aspx |title=Granules India Ltd., is pleased to announce the approval of its facilities in the recently conducted audit by US FDA |publisher=Granulesindia.com |date=2007-05-14 |accessdate=2010-09-30}}</ref>

In 2008, the Gagillapur plant started production of tablets. In 2010, Granules received U.S. FDA approval for its first Abbreviated New Drug Application (ANDA).<ref name="granulesindia1">{{cite web|url=http://www.granulesindia.com/Capacities_Capabilities_Gagillapur.aspx |title=Granules India Limited - Infrastructure - Equipment - Capacities & Capabilities |publisher=Granulesindia.com |date= |accessdate=2010-09-30}}</ref>

In 2011, Granules established Granules-OmniChem, a [[joint venture]] with Ajinomoto OmniChem to venture into Contract Research And Manufacturing Services(CRAMS) business with a manufacturing facility at Vizag SEZ.

In 2013, Granules opened a 10,000 sq. foot R&D facility at Pragathi Nagar in Hyderabad. In the same year the company signed an agreement to acquire Auctus Pharma, which includes twelve APIs in its product portfolio as well as key intermediates of those APIs.{{cn|date=March 2015}} It has two manufacturing facilities, an API facility in Vizag and an Intermediate facility in Hyderabad.


In June 2023, Granules India reported a cybersecurity breach, with the ransomware group [[LockBit]] claiming responsibility for the attack and alleging access to confidential data.<ref>{{cite news |last1=Singh |first1=Jagmeet |title=LockBit claims ransomware attack on pharma giant Granules India |url=https://techcrunch.com/2023/06/15/lockbit-ransomware-granules-india/ |publisher=[[TechCrunch]] |date=June 15, 2023}}</ref>
==Infrastructure==
==Infrastructure==
⚫
[[File:Granules GGP plant.jpg|thumb|300px|[[Gagillapur]] plant]]
Granules has seven manufacturing facilities; six are in India while the seventh is through a joint-venture with Hubei Biocase in Wuhan, China. The company also has two research centres, at Hyderabad and Pune.
Granules has seven manufacturing facilities; six are in India while the seventh is through a joint-venture with Hubei Biocase in Wuhan, China. The company also has two research centres, at Hyderabad and [[Pune]].


⚫
The [[Gagillapur]] facility is located near Hyderabad and has a Finished Dosage block, a PFI block and a research & development facility.{{citation needed|date=May 2018}} Granules commissioned the world's single largest PFI plant in Gagillapur in August 2003 with a batch size of 6 MT and an annual capacity of 7,200 MT per annum. The plant received its US FDA approval within six months of commissioning.{{citation needed|date=May 2018}}
⚫
[[File:Granules GGP plant1.jpg|thumb|right|Gagillapur Plant]]

The Gagillapur facility is located near Hyderabad and has a Finished Dosage block, a PFI block and a research & development facility.

⚫
Granules commissioned the world’s single largest PFI plant in Gagillapur in August 2003 with a batch size of 6 MT and an annual capacity of 7,200 MT per annum. The plant received its US FDA approval within six months of commissioning.

==People==
Granules India's Board of Directors include:

* Mr. C. Krishna Prasad : Chairman & Managing Director
* Mrs. Uma Chigurupati : Executive Director
* Mr. Harsha Chigurupati : Executive Director
* Mr. L.S. Sarma : Independent Director
* Mr. A.P. Kurian : Independent Director
* Mr. C. Parthasarathy : Independent Director
* Dr. Krishna Murthy Ella : Independent Director
* Mr. Arun Rao Akinepally : Independent Director
* Mr. K. B. Sankara Rao : Director


==See also==
==See also==
Line 71: Line 54:
==References==
==References==
{{Reflist}}
{{Reflist}}

{{Top Indian companies}}


[[Category:Pharmaceutical companies of India]]
[[Category:Pharmaceutical companies of India]]
[[Category:Companies based in Hyderabad, India]]
[[Category:Manufacturing companies based in Hyderabad, India]]
[[Category:Pharmaceutical companies established in 1984]]
[[Category:Pharmaceutical companies established in 1984]]
[[Category:Indian companies established in 1984]]
[[Category:1984 establishments in Andhra Pradesh]]
[[Category:Companies listed on the National Stock Exchange of India]]
[[Category:Companies listed on the Bombay Stock Exchange]]

Latest revision as of 19:31, 4 November 2024

Granules India Ltd.
Company typePublic
BSE: 532482
NSE: GRANULES
IndustryPharmaceuticals
Founded1984
FounderKrishna Prasad Chigurupati
HeadquartersHyderabad, Telangana, India
Area served
Worldwide
Key people
Krishna Prasad Chigurupati (CMD)
Sandeep Neogi (CFO)
GSR Prasad (COO)
ProductsParacetamol, Ibuprofen, Methocarbamol, Metformin, Guaifenesin
RevenueDecrease ₹4,506 crore (US$530 million) (FY24)[1]
Decrease ₹856 crore (US$100 million) (FY24)[1]
Decrease ₹405 crore (US$47 million) (FY24)[1]
Number of employees
2,789
Websitegranulesindia.com

Granules India Limited is an Indian multinational pharmaceutical manufacturing company based in Hyderabad. Granules manufactures several off-patent drugs, including Paracetamol, Ibuprofen, Metformin and Guaifenesin, on a large scale for customers in the regulated and rest of the world markets. Granules India Limited also operates in the contract research and manufacturing (CRAM) segment.[2][3]

History

[edit]

Granules India was formed in 1984 as Triton Laboratories. Triton produced Paracetamol API at its Bonthapally factory on the outskirts of Hyderabad.[4] Triton scientists found a more efficient way to produce the Paracetamol API, which led to lower capital and raw material requirements.[citation needed] In 1987, Triton became the only Indian company aside from Dr. Reddy's Laboratories to export pharmaceutical products to the U.S.[citation needed]

Though Triton was growing as an API manufacturer, management decided it could create a value added version of its product.[citation needed] In order to distinguish itself from competitors, Triton management pioneered the concept of manufacturing and selling in bulk granulated Paracetamol, also known as direct compressible grade material (DC), or "PFI".[citation needed] In 1990, it opened its second manufacturing facility at Jeedimetla to produce multiple APIs.

In 1991,[5] management set up a new entity, which was incorporated as Granules India Limited. Soon after Granules applied the PFI concept to other APIs, set up a PFI facility at Jeedimetla and began exporting the material to various markets including the U.S., Germany and Australia.[6]

In 1995,[5] Granules became a public company, after having initial public offerings on the Bombay and Hyderabad Stock Exchanges.[7]

In 2013, Granules India acquired Auctus Pharma for Rs 120 crore.[8]

In 2016, Granules India commissioned a new state of the art manufacturing unit that hosts facilities for Oncology and High Potent APIs. This new plant is located in Visakhapatnam.

In order to secure API for its Ibuprofen PFI, Granules formed a joint-venture with Hubei Biocause Heilen Pharmaceutical to create Granules Biocause in Wuhan, China.[9] In 2019, Granules India Limited announced its intention to divest its entire equity shareholding in Granules Biocause Pharmaceuticals Co. Ltd. by selling its stake to joint venture partner.[10]

In June 2023, Granules India reported a cybersecurity breach, with the ransomware group LockBit claiming responsibility for the attack and alleging access to confidential data.[11]

Infrastructure

[edit]
Gagillapur plant

Granules has seven manufacturing facilities; six are in India while the seventh is through a joint-venture with Hubei Biocase in Wuhan, China. The company also has two research centres, at Hyderabad and Pune.

The Gagillapur facility is located near Hyderabad and has a Finished Dosage block, a PFI block and a research & development facility.[citation needed] Granules commissioned the world's single largest PFI plant in Gagillapur in August 2003 with a batch size of 6 MT and an annual capacity of 7,200 MT per annum. The plant received its US FDA approval within six months of commissioning.[citation needed]

See also

[edit]

References

[edit]
  1. ^ a b c "Earnings Presentation - Q4 & Full Year FY24" (PDF). BSE. Granules India Limited. Retrieved 10 July 2024.
  2. ^ "Granules India signs deal with Matchland Pty Ltd".
  3. ^ "Granules India". Moneycontrol.com. 10 May 2007. Retrieved 10 December 2009.
  4. ^ "Triton Laboratories Ltd Company info".
  5. ^ a b "Granules India Limited – About Us – Milestones". Granulesindia.com. Archived from the original on 17 July 2010. Retrieved 30 September 2010.
  6. ^ "Granules ties up with GSK Healthcare R&D".
  7. ^ "Granules, Amneal Pharma get FDA nod". Business Standard. 2 August 2006. Retrieved 10 December 2009.
  8. ^ "Granules India acquires Auctus Pharma for Rs 120 crore". www.businesstoday.in. 5 November 2013. Retrieved 10 February 2020.
  9. ^ "Granules India takes stake in Chinese firm". In-pharmatechnologist.com. Retrieved 30 September 2010.
  10. ^ "Granules India to divest its stake in its joint venture located in China". Economic Times.
  11. ^ Singh, Jagmeet (15 June 2023). "LockBit claims ransomware attack on pharma giant Granules India". TechCrunch.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Granules_India&oldid=1255400053"